TABLE 3.
Adherence Rates by Subgroup
| Enrollment type | n | Mean adherence (%) | Median adherence (%) | Median CMG (%) | |||||
|---|---|---|---|---|---|---|---|---|---|
| MPRm | PDC | MRA | MPRm | PDC | MRA | ||||
| Minimum follow-up | |||||||||
| 3 months | FFS | 2,027 | 95.2 | 79.3 | 83.3 | 100.0 | 92.0 | 98.3 | — |
| 6 months | 1,657 | 94.7 | 77.5 | 81.6 | 100.0 | 91.5 | 97.8 | — | |
| 12 months | 1,212 | 93.9 | 74.8 | 79.0 | 100.0 | 90.3 | 96.8 | — | |
| 3 months | MA | 1,531 | 94.3 | 79.0 | 82.9 | 100.0 | 91.7 | 98.2 | — |
| 6 months | 1,243 | 93.5 | 76.6 | 80.6 | 100.0 | 90.7 | 97.2 | — | |
| 12 months | 887 | 92.6 | 74.2 | 78.4 | 100.0 | 89.5 | 96.2 | — | |
| Age, y | |||||||||
| < 65 | — | 50 | 95.5 | 79.4 | 82.4 | 100.0 | 94.9 | 99.7 | 0.3 |
| 65-74 | — | 834 | 94.4 | 79.3 | 83.1 | 100.0 | 92.5 | 98.5 | 1.5 |
| 75-84 | — | 1,899 | 94.9 | 79.2 | 83.2 | 100.0 | 91.8 | 98.1 | 1.9 |
| > 85 | — | 775 | 94.8 | 79.0 | 83.0 | 100.0 | 91.1 | 97.8 | 2.2 |
| Sex | |||||||||
| Female | — | 657 | 93.7 | 78.0 | 82.0 | 100.0 | 89.9 | 95.8 | 4.2 |
| Male | — | 2,901 | 95.1 | 79.4 | 83.4 | 100.0 | 92.2 | 98.6 | 1.4 |
| Race | |||||||||
| African American | — | 950 | 92.6 | 78.1 | 82.1 | 100.0 | 89.5 | 96.2 | 3.7 |
| Hispanic | — | 661 | 91.6 | 77.8 | 81.6 | 99.2 | 88.0 | 92.3 | 7.7 |
| Non-Hispanic White | — | 260 | 95.5 | 79.4 | 83.4 | 100.0 | 92.3 | 98.7 | 1.3 |
| Other | — | 1,248 | 96.9 | 82.2 | 86.1 | 100.0 | 93.1 | 98.7 | 1.3 |
| Diagnosisa | |||||||||
| Patients with E85.82 diagnosis | — | 1,189 | 95.0 | 78.0 | 82.0 | 100.0 | 91.0 | 98.0 | — |
| Patients without E85.82 diagnosis | — | 981 | 96.0 | 84.0 | 87.0 | 100.0 | 94.0 | 100.0 | — |
| Tafamidis formulationb | |||||||||
| Tafamidis free acid | 2,000 | 97.0 | 87.0 | 90.0 | 100.0 | 95.0 | 100.0 | — | |
| Tafamidis meglumine | 1,170 | 95.0 | 69.0 | 73.0 | 100.0 | 85.0 | 92.0 | — | |
| RUCA tier | |||||||||
| 1 Most urban | — | 3,206 | — | 80.6 | — | — | — | — | — |
| 2 | — | 373 | — | 80.5 | — | — | — | — | — |
| 3 | — | 118 | — | 81.3 | — | — | — | — | — |
| 4 Most rural | — | 140 | — | 75.1 | — | — | — | — | — |
| DCI quintile | |||||||||
| 1 Prosperous | — | 1,286 | — | 81.4 | — | — | — | — | — |
| 2 | — | 952 | — | 81.0 | — | — | — | — | — |
| 3 | — | 588 | — | 80.8 | — | — | — | — | — |
| 4 | — | 476 | — | 76.8 | — | — | — | — | — |
| 5 Distressed | — | 460 | — | 79.6 | — | — | — | — | — |
| Medicare cohort | |||||||||
| Disabled | — | 57 | 93.0 | 77.0 | 80.0 | 100.0 | 89.0 | 99.0 | — |
| Dualc | — | 375 | 94.0 | 83.0 | 88.0 | 99.0 | 92.0 | 97.0 | — |
| ESRD | — | 15 | 97.0 | 78.0 | 81.0 | 100.0 | 91.0 | 93.0 | — |
aOnly evaluated FFS patients.
bDenotes P < 0.0001 assessed by analysis of variance for mean adherence (MPRm, PDC, and MRA).
cPertains to patients enrolled in both Medicare FFS and Medicaid.
— = not applicable; CMG = continuous measure of medication gaps; DCI = Distressed Communities Index; ESRD = end-stage renal disease; FFS = Medicare Fee-for-Service; MA = Medicare Advantage; MPRm = modified medication possession ratio; MRA = medication refill adherence; PDC = proportion of days covered; RUCA = Rural-Urban Commuting Area; y = years.